Efficacy of tat-conjugated ritonavir-loaded nanoparticles in reducing HIV-1 replication in monocyte-derived macrophages and cytocompatibility with macrophages and human neurons

AIDS Research and Human Retroviruses

Volumn 27, Issue 8, 2011, Pages 853-862

  Borgmann, Kathleen ^a   Rao, Kavitha S ^b   Labhasetwar, Vinod ^b   Ghorpade, Anuja ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; CELL PENETRATING PEPTIDE; NANOPARTICLE; PEPTIDE; RITONAVIR; TRANSCRIPTION PEPTIDE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; CELL ISOLATION; CELL VIABILITY; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG CONJUGATION; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FETUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN TISSUE; MONOCYTE DERIVED MACROPHAGE; MONONUCLEAR PHAGOCYTE; NERVE CELL; NERVE CELL CULTURE; PRIORITY JOURNAL; PROTEIN SECRETION; VIRION; VIROGENESIS; VIRUS INDUCTION; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS SURVIVAL;

BRAIN; CELL SURVIVAL; CELLS, CULTURED; CROSS-LINKING REAGENTS; DRUG CARRIERS; DRUG COMPOUNDING; FEMALE; FETUS; GENE PRODUCTS, TAT; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MACROPHAGES; NANOPARTICLES; NEURONS; PARTICLE SIZE; PREGNANCY; PRIMARY CELL CULTURE; RITONAVIR; VIRION; VIRUS REPLICATION;

EID: 80051514051     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2010.0295     Document Type: Article

References (58)

1. Schrager LK and D'Souza MP: Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. JAMA 1998;280(1):67-71. (Pubitemid 28414999)
2. Wong HL, Chattopadhyay N, Wu XY, and Bendayan R: Nanotechnology applications for improved delivery of antiretroviral drugs to the brain. Adv Drug Deliv Rev 2010; 62(4-5):503-517.
3. Noursadeghi M, Ustianowski A, Elgalib A, and Miller R: Bacterial disease in HIV-infected patients: The blind spot of highly active antiretroviral therapy? J Acquir Immune Defic Syndr 2006;41(4):532-535.
4. Wong JK, Hezareh M, Gunthard HF, et al.: Recovery of replication- competent HIV despite prolonged suppression of plasma viremia. Science 1997;278(5341):1291-1295. (Pubitemid 27495741)
5. Grant I, Sacktor N, and McArthur J: HIV Neuurocognitive disorders. In: The Neurology of AIDS, 2nd ed. (Gendelman HE, Grant I, Everall I, Lipton SA, Swindells S, Eds.). Oxford University Press, New York, 2005.
6. Ances BM and Ellis RJ: Dementia and neurocognitive disorders due to HIV-1 infection. Semin Neurol 2007;27(1):86-92. (Pubitemid 46239043)
7. Sacktor N. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J Neurovirol 2002;8(Suppl 2): 115-121. (Pubitemid 36097787)
8. Aquaro S, Svicher V, Ronga L, Perno CF, and Pollicita M: HIV-1-associated dementia during HAART therapy. Recent Patents CNS Drug Discov 2008;3(1):23-33. (Pubitemid 351223181)
9. Koenig S, Gendelman HE, Orenstein JM, et al.: Detection of AIDS virus inmacrophages in brain tissue fromAIDS patients with encephalopathy. Science 1986;233(4768):1089-1093. (Pubitemid 16032241)
10. Asare E, Dunn G, Glass J, et al.: Neuronal pattern correlates with the severity of human immunodeficiency virus-associated dementia complex. Am J Pathol 1996;148:31-38.
11. Everall IP, Heaton RK, Marcotte TD, et al.: Cortical synaptic density is reduced in mild to moderate human immunodeficiency virus neurocognitive disorder. HNRC Group. HIV Neurobehavioral Research Center. Brain Pathol 1999;9(2):209-217. (Pubitemid 29157710)
12. Glass JD, Fedor H, Wesselingh SL, and McArthur JC: Immunocytochemical quantitation of human immunodeficiency virus in the brain: Correlation with dementia. Ann Neurol 1995;38:755-762.
13. Thomas SA: Anti-HIV drug distribution to the central nervous system. Curr Pharm Des 2004;10(12):1313-1324. (Pubitemid 38568084)
14. Rao KS, Ghorpade A, and Labhasetwar V: Targeting anti-HIV drugs to the CNS. Expert Opin Drug Deliv 2009;6(8): 771-784.
15. Nowacek AS, McMillan J, Miller R, Anderson A, Rabinow B, and Gendelman HE: Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: Implications for neuroAIDS therapeutics. J Neuroimmune Pharmacol 2010; 5(4):592-601.
16. Mahajan SD, Roy I, Xu G, et al.: Enhancing the delivery of anti retroviral drug "saquinavir" across the blood brain barrier using nanoparticles. Curr HIV Res 2010;8(5):396-404.
17. Cuzin L, Allavena C, Morlat P, and Dellamonica P: Boosted protease inhibitor-based or nonnucleoside reverse transcriptasebased HAART: Is there a best choice for antiretroviral-naive HIV-1 infected patients? AIDS Rev 2008;10(4):205-211.
18. Jain R, Agarwal S, Majumdar S, Zhu X, Pal D, and Mitra AK: Evasion of P-gp mediated cellular efflux and permeability enhancement of HIV-protease inhibitor saquinavir by prodrug modification. Int J Pharm 2005;303(1-2):8-19. (Pubitemid 41318017)
19. Johnston MI and Hoth DF: Present status and future prospects for HIV therapies. Science 1993;260(5112):1286-1293. (Pubitemid 23231972)
20. Vyas TK, Shah L, and Amiji MM: Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites. Expert Opin Drug Deliv 2006;3(5):613-628. (Pubitemid 44383489)
21. Becker ML, Remsen EE, Pan D, and Wooley KL: Peptidederivatized shell-cross-linked nanoparticles. 1. Synthesis and characterization. Bioconjug Chem 2004;15(4):699-709. (Pubitemid 38981943)
22. Torchilin VP: Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Adv Drug Deliv Rev 2008; 60(4-5):548-558. (Pubitemid 351215572)
23. Sawant R and Torchilin V: Intracellular transduction using cell-penetrating peptides. Mol Biosyst 2010;6(4):628-640.
24. Tuladhar SM, Noursadeghi M, Boyle JJ, Friedland JS, and Hornick P: Tuberculous pericardial effusion after coronary artery bypass graft. Ann Thorac Surg 2006;82(4):1519-1521. (Pubitemid 44402306)
25. Rao KS, Reddy MK, Horning JL, and Labhasetwar V: TATconjugated nanoparticles for the CNS delivery of anti-HIV drugs. Biomaterials 2008;29(33):4429-4438.
26. King JE, Eugenin EA, Buckner CM, and Berman JW: HIV tat and neurotoxicity. Microbes Infect 2006;8(5):1347-1357. (Pubitemid 43842005)
27. Sabatier J, Vives E, Mabrouk K, et al.: Evidence for neurotoxic activity of tat from human immunodeficiency virus type 1. J Virol 1991;65:961-967.
28. Haughey NJ, Nath A, Mattson MP, Slevin JT, and Geiger JD: HIV-1 Tat through phosphorylation of NMDA receptors potentiates glutamate excitotoxicity. J Neurochem 2001; 78(3):457-467. (Pubitemid 32729974)
29. Ofotokun I, Acosta EP, Lennox JL, Pan Y, and Easley KA: Pharmacokinetics of an indinavir-ritonavir-fosamprenavir regimen in patients with human immunodeficiency virus. Pharmacotherapy 2008;28(1):74-81.
30. Gendelman HE, Orenstein JM, Martin MA, et al.: Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J Exp Med 1988;167(4):1428-1441.
31. Ghorpade A, Nukuna A, Che M, et al.: Human immunodeficiency virus neurotropism: An analysis of viral replication and cytopathicity for divergent strains in monocytes and microglia. J Virol 1998;72(4):3340-3350. (Pubitemid 28175579)
32. Kutza J, Fields K, Grimm TA, and Clouse KA: Inhibition of HIV replication and macrophage colony-stimulating factor production in human macrophages by antiretroviral agents. AIDS Res Hum Retroviruses 2002;18(9):619-625. (Pubitemid 35356581)
33. Deshpande M, Zheng J, Borgmann K, et al.: Role of activated astrocytes in neuronal damage: Potential links to HIV-1-associated dementia. Neurotox Res 2005;7(3):183-192.
34. Bevilacqua M, Dominguez LJ, and Barbagallo M: Insulin resistance and the cardiometabolic syndrome in HIV infection. J Cardiometab Syndr 2009;4(1):40-43.
35. Broder S: The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res 2010; 85(1):1-18.
36. Richmond SR, Carper MJ, Lei X, Zhang S, Yarasheski KE, and Ramanadham S: HIV-protease inhibitors suppress skeletal muscle fatty acid oxidation by reducing CD36 and CPT1 fatty acid transporters. Biochim Biophys Acta 2010; 1801(5):559-566.
37. Lee CG, Gottesman MM, Cardarelli CO, et al.: HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 1998;37(11):3594-3601. (Pubitemid 28162914)
38. Curran A, Gutirerrez M, Deig E, et al.: Efficacy, safety and pharmacokinetics of 900/100mg of darunavir/ritonavir once daily in treatment-experienced patients. J Antimicrob Chemother 2010;24(7):1083-1084.
39. DeJesus E, Lalezari JP, Osiyemi OO, et al.: Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ ritonavir in antiretroviral-naive HIV type-1-infected adults. Antivir Ther 2010;15(5):711-720.
40. Nieminen TH, Hagelberg NM, Saari TI, et al.: Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir. Eur J Clin Pharmacol 2010;66(10):977-985.
41. Ter Heine R, Mulder JW, van Gorp EC, Wagenaar JF, Beijnen JH, and Huitema AD: Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients. Br J Clin Pharmacol 2010;69(5):475-483.
42. Cressey TR, Jourdain G, Rawangban B, et al.: Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy. AIDS 2010;24(14):2193-2200.
43. van Kampen JJ, Reedijk ML, Burgers PC, et al.: Ultra-fast analysis of plasma and intracellular levels of HIV protease inhibitors in children: A clinical application of MALDI mass spectrometry. PLoS One 2010;5(7):e11409.
44. Penzak SR, Robertson SM, Hunt JD, et al.: Echinacea purpurea significantly induces cytochrome P450 3A activity but does not alter lopinavir-ritonavir exposure in healthy subjects. Pharmacotherapy 2010;30(8):797-805.
45. Sekar V, Lavreys L, Van de Casteele T, et al.: Pharmacokinetics of darunavir/r and rifabutin co-administered in HIVnegative healthy volunteers. Antimicrob Agents Chemother 2010;54(10):4440-4450.
46. Bruce RD, Altice FL, Moody DE, et al.: Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir. J Acquir Immune Defic Syndr 2010; 54(5):511-514.
47. German P, Warren D, West S, Hui J, and Kearney BP: Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV. J Acquir Immune Defic Syndr 2010;55(3):323-329.
48. Bala I, Hariharan S, and Kumar MN: PLGA nanoparticles in drug delivery: The state of the art. Crit Rev Ther Drug Carrier Syst 2004;21(5):387-422. (Pubitemid 41647578)
49. Reddy M, Wu L, Kou W, Ghorpade A, and Labhasetwar V: Superoxide dismutase-loaded PLGA nanoparticles protect cultured human neurons under oxidative stress. Appl Biochem Biotechnol 2008;151(2-3):565-577.
50. Boykins RA, Mahieux R, Shankavaram UT, et al.: Cutting edge: A short polypeptide domain of HIV-1-Tat protein mediates pathogenesis. J Immunol 1999;163(1):15-20. (Pubitemid 29295818)
51. Crowe SM: Role of macrophages in the pathogenesis of human immunodeficiency virus (HIV) infection. Aust NZ J Med 1995;25(6):777-783. (Pubitemid 26022659)
52. Aquaro S, Bagnarelli P, Guenci T, et al.: Long-term survival and virus production in human primary macrophages infected by human immunodeficiency virus. J Med Virol 2002;68(4):479-488. (Pubitemid 35231773)
53. du Toit LC, Pillay V, and Choonara YE: Nano-microbicides: Challenges in drug delivery, patient ethics and intellectual property in the war against HIV/AIDS. Adv Drug Deliv Rev 2010;62(4-5):532-546.
54. Gupta U and Jain NK: Non-polymeric nano-carriers in HIV/ AIDS drug delivery and targeting. Adv Drug Deliv Rev 2010;62(4-5):478-490.
55. Destache CJ, Belgum T, Christensen K, Shibata A, Sharma A, and Dash A: Combination antiretroviral drugs in PLGA nanoparticle for HIV-1. BMC Infect Dis 2009;9:198.
56. Sharma P and Garg S: Pure drug and polymer based nanotechnologies for the improved solubility, stability, bioavailability and targeting of anti-HIV drugs. Adv Drug Deliv Rev 2010;62(4-5):491-502.
57. Bender AR, von Briesen H, Kreuter J, Duncan IB, and Rubsamen-Waigmann H: Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitro. Antimicrob Agents Chemother 1996;40(6):1467-1471. (Pubitemid 26169056)
58. Nowacek AS, Miller RL, McMillan J, et al.: NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery. Nanomedicine (Lond) 2009;4(8):903-917.